Trial reportJournal of thrombosis and haemostasis : JTH2020
The intestinal microbiome potentially affects thrombin generation in human subjects.
Trial report in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The intestinal microbiome potentially affects thrombin generation in human subjects.Journal of thrombosis and haemostasis : JTH · 2020Trial
- Plasma proteomic profiles of patients during oral anti-coagulant treatment with vitamin K antagonists.British journal of haematology · 2026Article
- Gut microbiota, plasma metabolites, and venous thromboembolism: a Mendelian randomization study.AMB Express · 2025Article
- The causal relationships between gut microbiota and venous thromboembolism: a Mendelian randomization study.Hereditas · 2025Article
- The gut microbiota in thrombosis.Nature reviews. Cardiology · 2025Review
- The potential roles of gut microbiome in porto-sinusoidal vascular disease: an under-researched crossroad.Frontiers in microbiology · 2025Review
- Proteomic Evolution from Acute to Post-COVID-19 Conditions.Journal of proteome research · 2024Article
- Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.Frontiers in immunology · 2024Review
- The Effects of Mammary GlandInternational journal of molecular sciences · 2023Article
- Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies.Journal of internal medicine · 2022Article
- Article
- Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.Journal of clinical medicine · 2022Review
- Integrated metagenomics and metabolomics analysis illustrates the systemic impact of the gut microbiota on host metabolism after bariatric surgery.Diabetes, obesity & metabolism · 2022Article
- Microbiome-associated human genetic variants impact phenome-wide disease risk.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.Journal of thrombosis and haemostasis : JTH · 2022Article
- Large-scale correlation analysis of deep venous thrombosis and gut microbiota.Frontiers in cardiovascular medicine · 2022Article
- An Update on MRMAssayDB: A Comprehensive Resource for Targeted Proteomics Assays in the Community.Journal of proteome research · 2021Article
- The gut microbiome and thromboembolism.Thrombosis research · 2020Review
- Gut Microbiota Dysbiosis in Patients with Intracranial Sino-Venous Thrombosis and Acute Ischemic Stroke in the Young.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe intestinal microbiome plays a versatile role in the etiology of arterial thrombosis. In venous thrombosis, driven chiefly by plasma coagulation, no such role has yet been established. We hypothesized that the intestinal microbiome composition affects coagulation in humans.
methodsWe used healthy donor fecal microbiota transplant (FMT) to experimentally change the microbiome composition in metabolic syndrome patients. Thirty-five subjects were randomized in a blinded fashion to healthy donor FMT or autologous FMT as a control in a 2:1 ratio. We measured thrombin generation at baseline and after 6 weeks using automated calibrated thrombinography, and we determined plasma abundance of 32 coagulation related proteins using a targeted mass spectrometry-based quantitative proteomics assay with heavy labeled internal standards.
resultsHealthy donor FMT prolonged the thrombinography lag time (median delta 0.0 versus 0.25 minutes, P = .039). The other thrombinography parameters showed no significant difference. Unsupervised cluster analysis suggested overall downregulation of coagulation related plasma proteins in subject clusters containing predominantly subjects that had a metabolic response to healthy donor FMT. FMT treatment status itself showed no clear clustering pattern with up- or downregulation, however, and proteins did not cluster according to an apparent biological grouping. DISCUSSION: A single healthy donor FMT tends to modestly suppress the onset thrombin generation in metabolic syndrome patients, representing initial proof-of-principle that the intestinal microbiota composition might affect the coagulation system in humans. The findings merit external validation as a role for intestinal microbiota in coagulation can have clinically important implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.